Home > Article > Technology peripherals > Honghu hip and knee replacement surgery robot independently developed by Minimally Invasive Robot-B (02252.HK) received NMPA marketing approval
Honghu hip and knee replacement surgery robot independently developed by Minimally Invasive Robot-B (02252.HK) received NMPA marketing approval
- WBOYforward
- 2023-09-22 15:09:03935browse
Minimally Invasive Robot-B (02252.HK) announced that the Honghu Orthopedic Joint Replacement Surgery Navigation and Positioning System (Honghu Hip and Knee Replacement Surgery Robot) independently developed by the group has officially passed the marketing approval of the National Medical Products Administration (NMPA). It became the first approved domestic hip and knee integrated orthopedic surgical robot equipped with a self-developed robotic arm.
As of the close of trading on September 18, 2023, MicroPort Robot-B (02252.HK) closed at HK$17.5, up 1.16%, with a turnover rate of 0.05%, a trading volume of 504,200 shares, and a transaction volume of HK$8.8212 million. Investment banks have mainly rated the stock as buy. In the past 90 days, a total of 2 investment banks have given buy ratings. The average target price in the past 90 days is HK$28.34. The latest research report from GF Securities gave MicroPort-B a buy rating and a target price of HK$26.69.
See the table below for details of agency ratings:
Minimally Invasive Robot-B has a Hong Kong stock market value of HK$16.47 billion, ranking third in the medical device II industry. The main indicators are shown in the table below:
The above content compiled based on public information is provided by Securities Star and generated through algorithms and has nothing to do with the position of this site. Securities Star strives but does not guarantee the accuracy, completeness, validity and timeliness of all or part of the information (including but not limited to text, video, audio, data and charts). If you have any questions, please contact us. This article is only a compilation of data and does not constitute any investment advice. Investments need to be made with caution and there are risks
〖Securities Star Hong Kong and US Stocks〗
This article does not constitute investment advice. There are risks in the stock market, so investment needs to be cautious.
The above is the detailed content of Honghu hip and knee replacement surgery robot independently developed by Minimally Invasive Robot-B (02252.HK) received NMPA marketing approval. For more information, please follow other related articles on the PHP Chinese website!